Late-stage differentiation Hepion’s two genomic-based liquid biopsy tests (mSEPT9 for HCC detection and a ctRNA platform) offer high sensitivity and the ability to distinguish between very early and early HCC stages, presenting a compelling differentiator for oncology diagnostics partnerships and potential payer discussions.

High-risk niche focus The core opportunity lies in high-risk cirrhotic patients where current screening misses up to 75% of cases. Partnerships with liver disease programs, transplant centers, and gastroenterology clinics could unlock prioritized adoption of liquid biopsy tests for surveillance and early detection.

IP and licensing leverage Global commercialization rights for the tests and the in-licensed ctRNA asset from Cirna Diagnostics create multiple collaboration avenues, including licensing, co-development, or distribution deals with diagnostics companies seeking liver cancer components or integrated theranostics solutions.

Strategic partnerships Recent activity shows a pattern of alliances with diagnostic developers (Cirna Diagnostics, New Day Diagnostics) and the possibility of expanding into multiplex panels (celiac, respiratory, H. pylori, HCC), enabling bundled offerings to large healthcare systems and value-based contracts.

Market readiness and funding The fast-growing global liquid biopsy market, combined with Hepion’s public company structure and substantial funding, suggests readiness for pilots with flagship accounts, co-development funding, and strategic investment discussions to accelerate commercialization in oncology diagnostics.